Roluperidone

Generic Name: Roluperidone

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₃FN_₂O_₂

CAS Number: 359625-79-9

Unique Ingredient Identifier: 4P31I0M3BF

Background: Roluperidone has been used in trials studying the treatment of Schizophrenia.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

BMS ends decades-long drought in novel schizophrenia drugs

Bristol-Myers Squibb's $14 billion acquisition of Karuna Therapeutics pays off with FDA approval for Cobenfy, a novel schizophrenia drug targeting cholinergic receptors. Cobenfy offers a new treatment approach with milder side effects compared to dopamine-blocking drugs, potentially leading to blockbuster sales. BMS plans to launch Cobenfy at $1,850 per month, with further clinical trials underway for additional indications.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy